SI3538525T1 - 3-substituirane propionske kisline kot inhibitorji alfa v integrina - Google Patents
3-substituirane propionske kisline kot inhibitorji alfa v integrinaInfo
- Publication number
- SI3538525T1 SI3538525T1 SI201731195T SI201731195T SI3538525T1 SI 3538525 T1 SI3538525 T1 SI 3538525T1 SI 201731195 T SI201731195 T SI 201731195T SI 201731195 T SI201731195 T SI 201731195T SI 3538525 T1 SI3538525 T1 SI 3538525T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- propionic acids
- integrin inhibitors
- substituted propionic
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662418848P | 2016-11-08 | 2016-11-08 | |
EP17801230.8A EP3538525B1 (en) | 2016-11-08 | 2017-11-07 | 3-substituted propionic acids as alpha v integrin inhibitors |
PCT/US2017/060376 WO2018089353A1 (en) | 2016-11-08 | 2017-11-07 | 3-substituted propionic acids as alpha v integrin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3538525T1 true SI3538525T1 (sl) | 2022-09-30 |
Family
ID=60409432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201731195T SI3538525T1 (sl) | 2016-11-08 | 2017-11-07 | 3-substituirane propionske kisline kot inhibitorji alfa v integrina |
Country Status (28)
Country | Link |
---|---|
US (2) | US10968219B2 (sl) |
EP (1) | EP3538525B1 (sl) |
JP (1) | JP7097358B2 (sl) |
KR (1) | KR102505629B1 (sl) |
CN (1) | CN110167935B (sl) |
AR (1) | AR110153A1 (sl) |
AU (1) | AU2017359023B2 (sl) |
CA (1) | CA3042707A1 (sl) |
CL (1) | CL2019001264A1 (sl) |
CO (1) | CO2019005824A2 (sl) |
DK (1) | DK3538525T3 (sl) |
EA (1) | EA038164B1 (sl) |
ES (1) | ES2925173T3 (sl) |
HR (1) | HRP20220990T1 (sl) |
HU (1) | HUE059708T2 (sl) |
IL (1) | IL266473B (sl) |
LT (1) | LT3538525T (sl) |
MA (1) | MA46743A (sl) |
MX (1) | MX2019005244A (sl) |
MY (1) | MY199931A (sl) |
PE (1) | PE20191647A1 (sl) |
PL (1) | PL3538525T3 (sl) |
PT (1) | PT3538525T (sl) |
RS (1) | RS63483B1 (sl) |
SI (1) | SI3538525T1 (sl) |
TW (1) | TWI763733B (sl) |
WO (1) | WO2018089353A1 (sl) |
ZA (1) | ZA201903665B (sl) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
CN110167935B (zh) * | 2016-11-08 | 2022-05-27 | 百时美施贵宝公司 | 作为αV整合素抑制剂的3-经取代的丙酸 |
AU2017359028A1 (en) * | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Azole amides and amines as alpha V integrin inhibitors |
KR102506324B1 (ko) * | 2016-11-08 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물 |
JP2020504120A (ja) | 2016-12-29 | 2020-02-06 | セントルイス ユニバーシティ | インテグリンアンタゴニスト |
EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
MX2019010267A (es) | 2017-02-28 | 2020-02-05 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
UY38353A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibición de integrina alfavbeta6 |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
KR102652797B1 (ko) | 2018-10-30 | 2024-04-02 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린의 억제를 위한 화합물 |
BR112021007213A2 (pt) | 2018-10-30 | 2021-08-10 | Gilead Sciences, Inc. | derivados de quinolina como inibidores de integrina alfa4beta7 |
CN109824495B (zh) * | 2019-02-02 | 2022-12-09 | 盐城师范学院 | 一种新型偶联反应在制备碳-碳键结构化合物中的应用 |
JP2022543465A (ja) | 2019-08-14 | 2022-10-12 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
AU1523199A (en) | 1997-11-26 | 1999-06-15 | Du Pont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists |
JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
WO2000009503A1 (en) * | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
ES2376161T3 (es) | 2001-01-29 | 2012-03-09 | Janssen Pharmaceuticals, Inc. | Indoles sustituidos y su utilización como antagonistas de integrinas. |
JP2006513218A (ja) * | 2002-12-20 | 2006-04-20 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物 |
BR0317600A (pt) * | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
WO2007141473A1 (en) | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
US8362271B2 (en) | 2009-09-04 | 2013-01-29 | Basf Se | Process for preparing 1-phenylpyrazoles |
ES2574927T3 (es) | 2009-10-29 | 2016-06-23 | Glaxosmithkline Llc | Piridinas bicíclicas y análogos como moduladores de sirtuina |
ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
WO2016134223A2 (en) | 2015-02-19 | 2016-08-25 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
EP3268369A4 (en) * | 2015-03-10 | 2018-08-08 | The Regents of The University of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
CN110167935B (zh) * | 2016-11-08 | 2022-05-27 | 百时美施贵宝公司 | 作为αV整合素抑制剂的3-经取代的丙酸 |
-
2017
- 2017-11-07 CN CN201780082473.2A patent/CN110167935B/zh active Active
- 2017-11-07 HU HUE17801230A patent/HUE059708T2/hu unknown
- 2017-11-07 EA EA201991122A patent/EA038164B1/ru unknown
- 2017-11-07 WO PCT/US2017/060376 patent/WO2018089353A1/en unknown
- 2017-11-07 HR HRP20220990TT patent/HRP20220990T1/hr unknown
- 2017-11-07 LT LTEPPCT/US2017/060376T patent/LT3538525T/lt unknown
- 2017-11-07 CA CA3042707A patent/CA3042707A1/en active Pending
- 2017-11-07 DK DK17801230.8T patent/DK3538525T3/da active
- 2017-11-07 MX MX2019005244A patent/MX2019005244A/es unknown
- 2017-11-07 ES ES17801230T patent/ES2925173T3/es active Active
- 2017-11-07 MY MYPI2019002576A patent/MY199931A/en unknown
- 2017-11-07 MA MA046743A patent/MA46743A/fr unknown
- 2017-11-07 SI SI201731195T patent/SI3538525T1/sl unknown
- 2017-11-07 US US16/347,844 patent/US10968219B2/en active Active
- 2017-11-07 PT PT178012308T patent/PT3538525T/pt unknown
- 2017-11-07 EP EP17801230.8A patent/EP3538525B1/en active Active
- 2017-11-07 PL PL17801230.8T patent/PL3538525T3/pl unknown
- 2017-11-07 PE PE2019000940A patent/PE20191647A1/es unknown
- 2017-11-07 AU AU2017359023A patent/AU2017359023B2/en active Active
- 2017-11-07 KR KR1020197016082A patent/KR102505629B1/ko active IP Right Grant
- 2017-11-07 RS RS20220759A patent/RS63483B1/sr unknown
- 2017-11-07 JP JP2019523576A patent/JP7097358B2/ja active Active
- 2017-11-08 TW TW106138533A patent/TWI763733B/zh active
- 2017-11-08 AR ARP170103105A patent/AR110153A1/es unknown
-
2019
- 2019-05-06 IL IL266473A patent/IL266473B/en unknown
- 2019-05-08 CL CL2019001264A patent/CL2019001264A1/es unknown
- 2019-06-04 CO CONC2019/0005824A patent/CO2019005824A2/es unknown
- 2019-06-07 ZA ZA2019/03665A patent/ZA201903665B/en unknown
-
2021
- 2021-02-24 US US17/184,179 patent/US11884661B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201903665B (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
EP3193608A4 (en) | Carm1 inhibitors and uses thereof | |
HRP20192119T8 (hr) | Pripravak i metoda za pomoć pri spavanju | |
EP3200588A4 (en) | Arginine methyltransferase inhibitors and uses thereof | |
EP3175023A4 (en) | Systems and methods for determining nucleic acids | |
EP3134536A4 (en) | Systems and methods for barcoding nucleic acids | |
EP3190682A4 (en) | Power supply system and method | |
EP3181085A4 (en) | Tracking system and tracking method using same | |
EP3238840A4 (en) | Method for recycling used absorbent article | |
EP3193611A4 (en) | Mk2 inhibitors and uses thereof | |
IL267239A (en) | New derivatives of phenylpropionic acid and their uses | |
EP3195129A4 (en) | Application centric distributed storage system and method | |
EP3397430A4 (en) | HEADREST SYSTEMS AND METHOD FOR USE | |
IL255054A0 (en) | Tetrahydronephthyridinyl propionic acid derivatives and their uses | |
EP3166523A4 (en) | Cryoablation method and system | |
EP3232039A4 (en) | Method and device for energy-saving ship navigation | |
EP3139918A4 (en) | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | |
EP3185880A4 (en) | Improved peptidyl calcineurin inhibitors | |
EP3217932A4 (en) | Surgical articles and methods for detection | |
EP3097101A4 (en) | Isoquinoline derivatives as mgat2 inhibitors | |
EP3094615A4 (en) | Terpene-derived acids and esters and methods for preparing and using same | |
HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
EP3209675A4 (en) | Compositions and methods for the detection of nucleic acids | |
EP3176097A4 (en) | Blank supply device and blank supply method using same | |
PT3134396T (pt) | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |